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Background. Current treatment of chronic hepatitis C with pegylated interferon and ribavirin has the ability to eliminate viral
infection in about half of the patients treated. Therapeutic options, for those with remaining chronic hepatitis, will remain limited
until novel antivirals become available in the future. Consensus interferon is currently available and has demonstrated clinical
eﬃcacy with superior invitro antiviral activity, but the maximum tolerated dose is not deﬁned. Methods. We assessed the eﬃcacy
of daily high-dose (24ug) consensus interferon with weight-based (1000–1200mg daily) ribavirin in HCV genotype 1-infected
non-responder patients. Results. Six adverse events were documented in ﬁve patients, and the trial was terminated with no subject
achieving viral clearance. Conclusions. The occurrence of serious adverse events eﬀectively deﬁned the upper limit of acceptable
dose, while also revealing that this dose did not oﬀer enhanced sustained viral clearance.
1.Introduction
The most commonly employed treatment of patients with
hepatitis C virus (HCV) infection who are treatment-
na¨ ıve consists of pegylated interferon-alfa and ribavirin with
sustained viral response (SVR) rates in genotype 1 patients
of up to 52% [1, 2]. Since the FDA approval of pegylated
interferonandribavirin,thereareanever-increasingnumber
of hepatitis C patients who have failed to respond to this
combination therapy. There is no standard of care for the
treatmentofpatientswhohavefailedtorespondtopegylated
interferonandribavirin[3].Consensusinterferon(CIFN),in
combination with ribavirin, has recently been approved for
this use. Patients with advanced ﬁbrosis may not have time
toawaitdevelopmentoffutureantiviralagentsandmayneed
to utilize currently available therapies.
CIFNhasmorepotent antiviral invitroactivitycompared
to other interferons [4, 5]. Currently, CIFN is approved for
initial or retreatment of persons infected with HCV. Recent
clinical trials report reasonable SVR rates (23% to 37%) in
the treatment of nonresponders to standard or pegylated
interferon and ribavirin using diﬀerent regimens of daily
CIFN and weight-based ribavirin dosage [6–8]. Cornberg
et al. found that an eight-week induction phase with CIFN
doses of 18μgf o l l o w e db y9μg for 40 weeks did not result
in a higher SVR compared to 9μg for 48 weeks, presumably
due to dose modiﬁcations in subjects receiving the induction
dose of CIFN. When the subgroup of patients receiving the
higher dose of CIFN, without early dose modiﬁcation, was
evaluated,40% achieved SVR [8] .T h e r ew a so n em u l t i c e n t e r
randomized control trial, the DIRECT trial, evaluating the
eﬃcacy of daily CIFN at doses of 9μgo r1 5μg with weight-
based ribavirin administration in the treatment of patients
unresponsive to prior pegylated interferon and ribavirin
treatment. Viral clearance was achieved in a dose-dependent
manner with greatest loss of HCV in the 15μgg r o u p[ 9].2 Hepatitis Research and Treatment
Although this trial suggested a dose-dependent rate of viral
clearance, there has been no dose-ranging information to set
the maximum tolerated dose of daily CIFN in this diﬃcult-
to-treat group of hepatitis C patients. Given the urgent need
of treatment for patients with advanced ﬁbrosis and limited
access to antiviral agents under development, evaluation of
available agents in novel dosing regimens is needed.
The aim of our clinical trial was to evaluate the eﬃcacy,
safety and tolerability of high-dose daily CIFN (24μg) with
weight-based ribavirin dosage given with maximal support
of patient adherence including blood cell growth factors.
Previous clinical trials did not evaluate this high dose of
daily CIFN in the treatment of non-responders to pegylated
interferon and ribavirin beyond an 8-week induction period
[9]. Since the previous data have suggested a possible dose-
dependent response to daily CIFN and ribavirin, determin-
ing the utility of a higher dosage of daily CIFN with weight-
based ribavirin will be important in this group of hepatitis C
patients with few eﬃcacious available treatment options.
2. Methods
Eligible subjects for our open-label trial were patients
infected with chronic hepatitis C genotype 1 previously
treated with either pegylated interferon alfa-2a or alfa-2b
and ribavirin. In addition, the subjects must have been
nonresponsive to prior treatment, deﬁned as the lack of a 2-
log drop of hepatitis C viral ribonucleic acid (HCV RNA)
from baseline at 12 weeks of therapy or the presence of
detectable HCV RNA at 24 weeks of therapy. All subjects
must have previously received a weight-based dosage of
ribavirin. At least one liver biopsy, consistent with chronic
hepatitis C without signiﬁcant alternative liver disease, must
have been performed prior to screening for enrollment into
the trial. All subjects, prior to participation, signed a consent
form approved by each institutional review board.
Thisstudywasanopen-labelpilottrial.Allstudysubjects
were treated with a daily 24μgd o s eo fC I F N( I n f e r g e n -
Valeant Pharmaceuticals, Costa Mesa, CA) given subcuta-
neously and a daily weight-based dose of ribavirin (1000–
1200mg per day). All patients were evaluated at weeks one,
two, and four of therapy and at subsequent four week inter-
vals unless additional urgent clinical evaluation was needed.
At each visit, subjects underwent physical examination and
clinical history detailing adverse events and completion of
the Beck Depression Inventory second edition (BDI-II).
Treatment was discontinued and the subject considered a
treatmentfailureifthepatientfailedtoachieveearlyvirologic
response (EVR) deﬁned as less than a 2-log drop of HCV
RNA from baseline at Week 12 of therapy, or had detectable
HCV RNA at or after Week 24 of therapy. Sustained viral
response (SVR) was deﬁned as an undetectable HCV RNA
level using Quest Diagnostics (Madison, NJ) Heptimax and
TMA serum assays 24 weeks after completion of 48 weeks of
treatment.
Potential subjects for this clinical trial were recruited
from three hepatology practices in New York. Compliance
with the experimental protocol was assessed by the subjects’
self-reported administration of ribavirin and the return of
Table 1: Demographics and baseline data.
Patient Characteristic Results
Ethnicity:
Caucasian 61.5%
Hispanic 30.8%
African-American 7.7%
Weight (kilograms)
Mean ± SEM 84.0 ±14.9
Histology
∗
Stage 1-2 3
Stage 3 5
Stage 4 5
Response to prior treatment (n)
Null response 10
Partial response 3
WBC count (k/μL)
Mean ± SEM 0.3 ±1.5
Hemoglobin (g/dL)
Mean ±SEM 14.6 ±1.4
Platelet count (k/μL)
Mean ±SEM 194.9 ±68.0
∗Fibrosis stage deﬁned as modiﬁed Ishak score determined as deﬁned by
Theise [10].
used CIFN vials. In addition, the trial had a data safety
monitor (DSM), who assessed the safety of this trial at
speciﬁed time points during the study. The DSM was an
independent physician with extensive clinical experience
with treatment of patients with hepatitis C infection.
The subject’s baseline demographics were compared
using Student’s t-test, chi-square and Fisher’s exact tests.
Response rates between partial and null responders were
compared using chi-square and Fisher’s exact tests.
3. Results
Thirteen subjects (8 men) with a mean age of 55-years were
enrolled in this study. The median baseline HCV RNA level
was 3,300,000IU/mL with only two subjects with levels less
than 1,000,000IU/mL. Ten patients had advanced ﬁbrosis
(Table1).During prior initial therapy, tenof thesubjectshad
failed to achieve loss of HCV RNA by 12 weeks of therapy.
T h r e es u b j e c t sh a ds h o w na2 - l o gd e c r e a s ei nH C VR N Ab y
12weeksbuthadremainedHCVRNAdetectableat24weeks
of therapy.
The trial was terminated early due to the occurrence of
serious adverse events (n = 6) in ﬁve patients. These serious
adverse events included abdominal wall abscess requir-
ing hospitalization, severe dehydration, and hypotension
resulting in metabolic derangements, loss of consciousness,
anemia, and ventricular tachycardia. In addition, one subject
discontinued therapy due to disabling fatigue. The trial
had initially been planned to enroll thirty subjects at this
interferon dose. The study termination decision was made
by the Principal Investigator on the advice of the DSM after
assessing the frequency of serious toxicity while no patientHepatitis Research and Treatment 3
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Figure 1: The graph shows the viral kinetics of the 13 subjects
during treatment with CIFN and weight-based ribavirin. None of
the subjects with an initial drop in HCV RNA, including subject
11 who had transient undetectable HCV RNA at week 20, failed to
achieved a sustained loss of HCV RNA.
had achieved a sustained loss of HCV RNA. The severity
and frequency, of serious adverse events, are evidence that
the high-dose aggressive treatment regimen of this study
deﬁnedanupperdoselimitoftolerabilityforCIFN-ribavirin
therapy.
Subjects were discontinued from treatment, according to
protocol, when therapy was judged to be futile or for adverse
events. Only four subjects received 24 weeks of treatment.
The median maximal decrease of HCV RNA from baseline
on treatment was 3,135,000IU/ml. Nine subjects (69%) had
greater than a 2-log drop from baseline HCV RNA while
on treatment. One of these had transient loss of HCV but
subsequently experienced a viral breakthrough. The four
subjects who received 24 weeks of therapy all had partial
viral response after 12 weeks of therapy, but had detectable
hepatitis C virus at week 24 and therapy was discontinued as
they were deemed non-responders (Figure 1).
T h r e es u b j e c t sw i t hp a r t i a lv i r a lr e s p o n s ep r e m a t u r e l y
discontinued therapy due to serious adverse events. There
were three subjects still on therapy when the trial was halted.
One subject had greater than a 2-log drop in HCV RNA
level from baseline by week 8 of therapy, but the HCV RNA
level at the time of termination had markedly increased, and
there was no longer a 2-log drop in the HCV RNA level
from baseline at that point. The second subject did have a
greater than 2-log decrease from baseline HCV RNA level
after16weeksoftherapy,butby20weeksthehepatitisCviral
level had increased over 1-log from the nadir level. The third
subject did not have a 2-log decline from baseline viral level
after 12 weeks of therapy and was deemed a non-responder.
The ﬁnal three subjects were non-responders to the study
medications at the time of discontinuation of therapy due
to adverse events.
There were three subjects with greater than a 2-log
drop in viral level by four weeks of therapy. One of these
subjects could not tolerate therapy and did not complete
12 weeks of therapy. Another was a nonresponder at 24
weeks of therapy. The third subject was still on study
medication when the clinical trial was halted, however, while
on therapy there was marked increase in HCV RNA level. All
three subjects who had greater than a 2-log drop from the
baseline viral level after four weeks of therapy were partial
responders to previous pegylated interferon and ribavirin
therapy compared to none of the prior null responders
(P<. 04).
The most common adverse events were fatigue (n = 12)
and ﬂu-like symptoms (n = 1 2 ) ,a n o r e x i a( n = 10),
anxiety/depression(n = 7),andinsomnia(n = 7).Themean
decrease in body weight during the experimental protocol
was 8.1±5.8kilograms. The median increase in BDI-II score
was 9 ± 10.1. Serious adverse events (n = 6) occurred in
ﬁve patients and included abdominal wall abscess, severe
dehydration, hypotension, and ventricular tachycardia all
requiring hospitalization and loss of consciousness and
anemia. These events occurred within the ﬁrst six to 16
weeks of therapy. Two subjects (15%) had their dose of
CIFN reduced during the trial from 24μgt o1 5μgd a i l y .F i v e
subjects (38.5%) had a dose reduction of ribavirin and one
of the ﬁve subjects had ribavirin discontinued. The mean
decrease in hemoglobin level from baseline to nadir was
3.6 ± 1.6g/dL with eight subjects receiving epoetin alpha
injections.
No subject had a decrease in absolute neutrophil count
below 500/μL. The mean decrease in WBC level from
baseline to nadir was 4,200 ± 1,300/μL. The mean decrease
in platelet count from baseline was 104,000 ±5,200/μL.
4. Discussion
Almost half the patients with HCV genotype 1 infection
are left with residual infection following treatment with
pegylated interferon and ribavirin. Evaluation of currently
availableagentstooptimizetherapeuticeﬃcacyisimportant,
particularly for patients with advanced hepatic ﬁbrosis.
Previous studies demonstrate promising SVR rates of
23% to 37% using daily CIFN and ribavirin in the retreat-
ment of non-responders to the combination of standard
or pegylated interferon and ribavirin [6–8]. HCV clearance
by CIFN appears to be a dose-related response [8, 9, 11].
The eﬃcacy of high-dose CIFN, however, may be limited by
tolerability and dose reductions for adverse events. There is
no study deﬁning the dose-limiting toxicity of CIFN used
with ribavirin. One study, by B¨ ocher et al., compared the
eﬃcacy of CIFN and ribavirin with high-dose induction
(9μgdaily for 24 weeks followed by 9μgthree times perweek
f o r2 4w e e k s )t ol o w e r - d o s et r e a t m e n t( C I F N1 8 μg three
times per week for 12 weeks, followed by 9μg three times
per week for 36 weeks) in those patients who had previously
failed treatment with interferon and ribavirin therapy. The
week 12 and 24 responses were superior in the high- versus4 Hepatitis Research and Treatment
low-dose group (P<. 05), but the SVR rates were identical
at 26%. This suggests that the initial positive eﬀect of the
24 weeks of high-dose daily induction was lost after dose
reduction to three times per week treatment [12].
Kaiser etal. from Germany evaluated an induction dose
of daily CIFN of 27μg for four weeks followed by 18μgf o r
eight weeks versus 18μg for 12 weeks in 120 patients infected
with HCV who were previous non-responders to pegylated
interferon and weight-based ribavirin [6]. No ribavirin was
given during the induction time period. The SVR rate was
44% in the high-dose group compared to 39% in the lower-
dose group. The rate of discontinuation of therapy was 10%
in the higher dose arm, and CIFN dose was reduced in 17%.
Since this study required signiﬁcant dose reductions without
blood cell growth factor support, the ability to assess the
eﬃcacy potential of high-dose daily CIFN was limited.
Another study by Cornberg and colleagues investigated
theeﬃcacyofCIFNplusribavirininHCVpatientswhowere
non-responders to standard interferon and ribavirin [8].
Consensus interferon dosing with 18μg for the ﬁrst 8-weeks
of treatment resulted in an enhanced ﬁrst-phase HCV-RNA
decay suggesting higher antiviral eﬃcacy of a higher dose of
CIFN, but this did not translate to a better SVR, presumably
due to dose modiﬁcations [8]. Based on the suggestion of a
dose-dependent response and a superior response to high-
dose CIFN, our trial sought to determine the upper limit of
tolerability of CIFN dose in these diﬃcult-to-treat patients.
Previous partial responders to pegylated interferon and
weight-based ribavirin as compared to null responders had
better viral kinetic responses with all three partial responders
having greater than a 2-log drop in HCV RNA from baseline
viral level by week four. This response, however, did not
translate into a higher overall eﬃcacy since these subjects
could not tolerate continued therapy and viral response did
not decline to undetectable levels.
This trial used a sustained high daily dose (24mg)
of CIFN, a treatment regimen which showed promising
early results in achieving a decline in HCV RNA levels
in a population of subjects resistant to prior therapy. The
major factor leading to termination of this study was the
occurrence of serious adverse events. Although each event
was not unique in patients receiving interferon ribavirin
treatment, the occurrence of frequent serious adverse events
in a small patient population raised signiﬁcant concern.
The abdominal wall abscess was related to injection site
infection. The development of dehydration and hypotension
was related to anorexia and severe lassitude. The episode of
loss of consciousness may have been related to anorexia and
anemia. The observed adverse events, even including cardiac
arrhythmias, have been reported previously in patients
receiving interferon alfa and ribavirin. The frequency and
severity of adverse events, however, eﬀectively determined
theupperlimitoftolerabilityofdailyconsensusinterferonto
be less than the 24μg daily dose when used in combination
with weight-based ribavirin. This observation is important
since the eﬃcacy results of the prior studies left open the
possibility of greater eﬃcacy of high-dose CIFN.
Despite use of blood cell growth factors and maximal
support of experienced investigators, this high-dose of daily
CIFN therapy in combination with a weight-based ribavirin
dose was not tolerated due to serious adverse events. Most
of the subjects required epoetin alfa injections for therapy-
associated anemia. Even in the subjects who could tolerate
high-dose CIFN therapy with weight-based ribavirin, sus-
tained loss of HCV was not achieved by 24 weeks.
We cannot recommend this higher daily 24μgd o s eo f
CIFNincombinationwithweight-basedribavirin.Ourstudy
eﬀectively deﬁnes the upper limit of tolerability of daily
CIFN dosage when used in combination with ribavirin.
Furthermore, this high dosage of CIFN and weight-based
ribavirin combination treatment was ineﬀective in erad-
icating hepatitis C virus in patients who failed previous
pegylated interferon and ribavirin therapy.
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